Lignans are plant secondary metabolites
with a wide range of reported
health-promoting bioactivities. Traditional routes toward these natural
products involve, among others, the extraction from plant sources
and chemical synthesis. However, the availability of the sources and
the complex chemical structures of lignans often limit the feasibility
of these approaches. In this work, we introduce a newly assembled
biosynthetic route in E. coli for the
efficient conversion of the common higher-lignan precursor (+)-pinoresinol
to the noncommercially available (−)-pluviatolide via three intermediates. (−)-Pluviatolide is considered a crossroad
compound in lignan biosynthesis, because the methylenedioxy bridge
in its structure, resulting from the oxidation of (−)-matairesinol,
channels the biosynthetic pathway toward the microtubule depolymerizer
(−)-podophyllotoxin. This oxidation reaction is catalyzed with
high regio- and enantioselectivity by a cytochrome P450 monooxygenase
from Sinopodophyllum hexandrum (CYP719A23),
which was expressed and optimized regarding redox partners in E. coli. Pinoresinol-lariciresinol reductase from Forsythia intermedia (FiPLR), secoisolariciresinol
dehydrogenase from Podophyllum pleianthum (PpSDH), and CYP719A23 were coexpressed together with a suitable
NADPH-dependent reductase to ensure P450 activity, allowing for four
sequential biotransformations without intermediate isolation. By using
an E. coli strain coexpressing the
enzymes originating from four plants, (+)-pinoresinol was efficiently
converted, allowing the isolation of enantiopure (−)-pluviatolide
at a concentration of 137 mg/L (ee ≥99% with 76% isolated yield).